Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

To assess the efficacy, safety and pharmacokinetics in subjects treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).
Not Available
Phase II
Adults
Not Available
Not Available
Zic, John
International
Vanderbilt University
08-23-2018
Treatment
VICCDERM18107
NCT03292406

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Clinical Diagnosis of CTCL stage IA, IB, or IIA with biopsy within last 3 months

Have BSA involvement corresponding to stages IA, IB or IIA CTCL with at least 3 distinct lesions



Exclusion Criteria:

CTCL that is stage IIB or great or stage IIA with stage N2 with >5% circulating Sezary cells or CD8+ or large cell transformation or Progressive CTCL

History of autoimmune disease

Laboratory test values at screening outside of the normal range and judged clinically significant by the investigator

Current participation in another clinical trial of a drug or device or past participation within 4 weeks before Baseline or subject is in exclusion period from a previous clinical trial

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: